Γ-glutamyl transpeptidase as a response predictor when using α-interferon to treat hepatitis C

D. H. Van Thiel, L. Friedlander, P. Malloy, H. I. Wright, A. Gurakar, S. Fagiuoli, W. Irish

Research output: Contribution to journalArticle

Abstract

Backgound/Aims: This study was performed to identify response predictors for Interferon therapy given to patients with chronic hepatitis C. Materials and Methods: The biochemical measures of liver injury that characterize viral hepatitis due to hepatitis C were followed prospectively in 84 individuals treated with α-Interferon. In addition, the liver histology and the hepatic iron content of these same individuals, prior to the initiation of Interferon therapy, were determined. Results: Patients not responding to the interferon therapy showed an increase in liver iron content from an average of 337 ug/g wet weight. In responder to a value of 1075 μg/g wet weight in non responders. γ-glutamyl transpeptidase levels in responders were significantly lower than in partial or non-responders. Conclusions: Both the hepatic iron content of the liver and the γ-glutamyl transpeptidase value prior to treatment were able to predict a clinical response to Interferon therapy. More importantly, the γ-glutamyl transpeptidase level measured in serum could be used to monitor the IFN response during treatment and was found to predict clinical exacerbations of hepatitis following withdrawal of interferon therapy.

Original languageEnglish (US)
Pages (from-to)888-892
Number of pages5
JournalHepato-Gastroenterology
Volume42
Issue number6
StatePublished - Dec 1 1995
Externally publishedYes

ASJC Scopus subject areas

  • Hepatology
  • Gastroenterology

Fingerprint Dive into the research topics of 'Γ-glutamyl transpeptidase as a response predictor when using α-interferon to treat hepatitis C'. Together they form a unique fingerprint.

  • Cite this

    Van Thiel, D. H., Friedlander, L., Malloy, P., Wright, H. I., Gurakar, A., Fagiuoli, S., & Irish, W. (1995). Γ-glutamyl transpeptidase as a response predictor when using α-interferon to treat hepatitis C. Hepato-Gastroenterology, 42(6), 888-892.